GSK will buy Bel­lus Health for $2B, set­ting up show­down with Mer­ck

GSK is dish­ing out $2 bil­lion to ac­quire Bel­lus Health, the British phar­ma gi­ant an­nounced Tues­day morn­ing, stok­ing more M&A buzz amid a wide­spread slow­down for biotech deal­mak­ing.

In of­fer­ing $14.75 per share — a 103% pre­mi­um to Bel­lus’ clos­ing price on Mon­day — GSK is buy­ing its way in­to a block­buster ri­val­ry with Mer­ck. For years, Bel­lus Health has built its sto­ry around chal­leng­ing gi­ant Mer­ck in de­vel­op­ing a P2X3 re­cep­tor an­tag­o­nist to treat chron­ic cough. Now, it’s up to GSK to prove Bel­lus’ cam­lip­ix­ant — pro­vid­ed the Phase III da­ta do turn up pos­i­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA